Peptide Cancer Vaccine Market, By Type (Peptide-Pulsed Dendritic Cancer Vaccine, Personalized Peptide Vaccine, Multivalent Peptide Vaccine, and Others), and By Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI503423 | Publish Date: March 2024 | No. of Pages: 170

Peptide Cancer Vaccine MarkeT Overview

Peptide Cancer Vaccine Market was valued at US$ 6.9 Billion in 2024 and is projected to grow at a CAGR of 7.9%to reach US$ 13.7 Billion by 2034.Peptide are amino acids which makes up certain proteins that are needed by skin. Addition of peptides helps in stimulation of skin for making collagen. Pituitary gland produces peptides. Peptidyl transferase act as an enzyme for peptide synthesis.  Synthetic Peptide vaccines consist of 20 to 30 amino acids which contains specific epitope of corresponding antigen against various diseases. Synthetic peptide based drugs that are labelled by radio-chemically different techniques are used in routine clinical applications for diagnosis & therapy of diseases. Peptide receptor radionuclide therapy (PRRT) with radiolabeled pharmaceuticals has become suitable & promising next generation therapy method for inoperable patients who are having metastatic tumor.  Various advantages of peptide vaccines has helped in enabling the peptides to be preferred in vaccine technology. Easy, rapid, inexpensive and high purity synthesis of peptides by using microwave assisted solid-phase peptide synthesis method has become the important advantage for use of peptides in vaccine systems. Synthesized peptide antigens are fully characterized by analytical methods. Peptide vaccines are typically water soluble and has high stability. Peptide vaccines are customized by using peptide epitope of one or more antigens. Peptide receptor radionuclide therapy (PRRT) and radiolabeled somatostatin (SST) peptide analogues are highly effective treatment agents. Peptide analogues are metabolically stable in clinical applications. Bombesin and somatostatin antagonist peptide analogues has become best for receptor targeting. Peptides produced for vaccines, drugs, and therapeutics has become the solution for incurable diseases like cancer and lots of epidemic diseases. Peptide cancer vaccines are designed which is based on epitope peptides that elicit humoral & cellular immune responses by targeting TAAs (tumor-associated antigens) or TSAs (tumor-specific antigens). Cancer has ranked second leading cause of death in the world. According to (PMC), around 10 million deaths are being reported in 2020. Peptide based vaccines is a vaccination approach which has minimal side-effects that uses synthetic tumor-associated, specific peptides, or combination of peptides that are designed to designed to elicit peptide-specific T cells. Peptide vaccines has become the important part of new generation vaccine systems. However, increasing development in bioengineering & biotechnology sector, antibiotic drug development, cancer diagnostic & treatment, production of vaccines has given positive impact on Peptide Cancer Vaccine Market

Peptide Cancer Vaccine MarkeT Dynamics

   Rising prevalence of cancer diseases & rate of urbanization

Rising prevalence of cancer disease and rate of urbanization is one of the leading factors for the Peptide Cancer Vaccines Market growth. Urbanization has given rise in consumption of western food, processed food, frozen packed foods, alcohol, caffeine, which are unhealthy and affect the health of human being. Urbanization has given rise in disposable income which allows the individual to enhance their lifestyle, spending less on cereals, millets, fruits, vegetables, spending more on processed foods and beverages, consuming high amount of red meat and animal derived food, fats & oils, sugar, sodium, which has affected the health. Unhealthy lifestyle like Smoking, alcohol intake, low fruits and vegetable consumption, lack of exercise, low energy consumption, consumption of fat rich diet, high intake of animal derived food like red meat, rising obesity has given rise in cancer diseases. Urbanization has caused unhealthy lifestyle, change in diet, obesity, lack of exercise, pollution, late marriages fewer children, no breast feeding or lesser feeding for less duration, early menarche, late menopause, which has become major contribution in global rise of breast cancer. According to ‘The World Cancer Report 2020’ it was determined that incidence of breast cancer is consistently rising in India due to high socio-economic status and rapid urbanization. For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that breast cancers, pancreas, prostate, colorectal and lung cancers increasing with rate of urbanization. 90th percentile was maximum increase rate of breast cancer. 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, 95th percentile for lung cancer and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. However, the growth in breast cancer and population in urban areas boosts the demand for Peptide Cancer Vaccines market.

Restrains:

Many challenges are considered while developing peptide based cancer vaccines. When algorithm for predicting T cell epitopes are used extensively, their sensitivity & accuracy are restricted because epitope spatial configuration alters when antigen binds to cell surface receptors, and due to this reason false-negative and false-positive result may occur. Due to vast heterogeneity in MHC alleles in human population and MHC restrictions developing peptide based vaccines for global use is difficult. However, MHC restrictions and some challenges while developing peptide cancer vaccine may somewhat restrain the target market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Peptide Cancer Vaccine MarkeT Segmentation

Peptide Cancer Vaccine Market - segmentation

The Peptide Cancer Vaccine market is segmented based on type, application and region.

On the basis of Type, the Peptide Cancer Vaccine market is segmented into Peptide-Pulsed Dendritic Cancer Vaccine, Personalized Peptide Vaccine, Multivalent Peptide Vaccine, and others. On the basis of Application the target market is segmented into Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, and others.

Regional Insights:

On region the Peptide Cancer Vaccine Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising prevalence of cancer diseases, rising research & development activities, increase in use of peptide therapeutics, robust healthcare infrastructure, is anticipated to increase demand for Peptide Cancer Vaccine in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Type - Peptide-Pulsed Dendritic Cancer Vaccine, Personalized Peptide Vaccine, Multivalent Peptide Vaccine, and others

By Application - Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, and others

 

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Peptide Cancer Vaccine Market report based on type, application, and region:

Peptide Cancer Vaccine Market, By Type:

  • Peptide-Pulsed Dendritic Cancer Vaccine
  • Personalized Peptide Vaccine
  • Multivalent Peptide Vaccine
  • Others

Peptide Cancer Vaccine Market, By Application:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Others

Peptide Cancer Vaccine Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Peptide Cancer Vaccine MarkeT Key Players

The key players operating the Peptide Cancer Vaccine Market includes, Boston Biomedical, Immatics N.V., VAXON Biotech, GlaxoSmithKline PLC., ISA Pharmaceuticals, TapImmune, Ultimovacs, Generex Biotechnology, Onco Therapy Science Inc., Moderna Inc., and others.

Recent Development:

  • In September 2022, Immatics N.V., has announced the comprehensive preclinical data set for TCR Bispecific Candidate IMA402 targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022, which was held in Paris, France in September 9 to 13 in 2022. TCR Bispecific Candidate IMA402 is a next generation, half-life extended TCR Bispecific that targets HLA-A*02:01-presented peptide that is derived from ‘PRAME’. IMA402 has determined enhanced anti-tumor activity in vivo & thus reduced T cell engager-associated toxicities as part of in vitro safety profile. IMA402 has suggested potential for favorable dosing regimen in patients with prolonged drug exposure at therapeutic levels.

Peptide Cancer Vaccine MarkeT Company Profile

  • Immatics N.V.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Boston Biomedical
  • VAXON Biotech
  • GlaxoSmithKline PLC.
  • ISA Pharmaceuticals
  • TapImmune
  • Ultimovacs
  • Generex Biotechnology
  • Onco Therapy Science Inc.
  • Moderna Inc.

 “*” marked represents similar segmentation in other categories in the respective section

Peptide Cancer Vaccine MarkeT Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Segment Trends
    • Peptide-Pulsed Dendritic Cancer Vaccine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Personalized Peptide Vaccine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Multivalent Peptide Vaccine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
  6. Market Segmentation, By Application, 2024 – 2034, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Segment Trends
    • Breast Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Lung Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Prostate Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Colorectal Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Pancreatic Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
  7. Global Market, By Region, 2024 – 2034, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
      • Y-o-Y Growth Analysis (%), 2024 – 2034
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Application, 2024 – 2034
      • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  1. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  2. Company Profiles
  • Boston Biomedical
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Immatics N.V.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • VAXON Biotech
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline PLC.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • ISA Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • TapImmune
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Ultimovacs
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Generex Biotechnology
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Onco Therapy Science Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Moderna Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The Peptide Cancer Vaccine Market is segmented into type, application, and region.

Peptide Cancer Vaccine Market is driven by factors like rising prevalence of cancer disease and rate of urbanization.

By region, the Peptide Cancer Vaccine market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.

The key players operating the Peptide Cancer Vaccine Market includes, Boston Biomedical, Immatics N.V., VAXON Biotech, GlaxoSmithKline PLC., ISA Pharmaceuticals, TapImmune, Ultimovacs, Generex Biotechnology, Onco Therapy Science Inc., Moderna Inc., and others.